Bas W.G. van Rhijn - Concepedia

Author

Bas W.G. van Rhijn

Also Known As

B. W. G. van Rhijn, B.W. G. van Rhijn, B.W.G. Van Rhijn, B.W.G. van Rhijn, B.W.G.V. Rhijn, Bas W G van Rhijn, Bas W. G. van Rhijn, Bas W.G van Rhijn, Bas W.G. Van Rhijn, Bas W.G. van Rhijn

269

Publications

20.5K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute University Health Network University of Regensburg Princess Margaret Cancer Centre Charles University

About

Bas W.G. van Rhijn is an author at The Netherlands Cancer Institute specializing in urology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	49	9K
2	Pathology	18	18	2.3K
3	Health Sciences	3	3	132
4	Public Health	3	4	636
5	Cell Biology	1	1	219

Bas W.G. van Rhijn

Publications

11.5K

Citations

H-Index

Page 1

	Year	Citations
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 Marko Babjuk, Andreas Böhle, Maximilian Burger, European Urology Urological ResearchUrologySurgical OncologyUrologic Cancer EpidemiologyGenitourinary Cancer	2016	2.3K
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update Morgan Rouprêt, Marko Babjuk, Éva Compérat, European Urology Urological ResearchSurgical OncologyUrologyGenitourinary CancerUrology Guidelines	2015	1.3K
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update Morgan Rouprêt, Marko Babjuk, Maximilian Burger, European Urology Urological ResearchUrologySurgical OncologyUrologic Cancer EpidemiologyGenitourinary Cancer	2020	930
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy Roland Seiler, H.A.D.M. Ashab, Nicholas Erho, European Urology UrologyMolecular SubtypesGenitourinary CancerTumor HeterogeneityMedicine	2017	775
European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update Morgan Rouprêt, Marko Babjuk, Éva Compérat, European Urology Urological ResearchUrologyGenitourinary CancerEuropean GuidelinesMedicine	2013	450
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel Richard Sylvester, Óscar Rodríguez, Virginia Hernández, European Urology Urological ResearchUrologyCancer RiskUrologic Cancer EpidemiologyCancer Epidemiology	2021	415
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome Bas W.G. van Rhijn, André N. Vis, Theodorus van der Kwast, Journal of Clinical Oncology	2003	319
FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy Lucie C. Kompier, Irene Lurkin, Madelon N.M. van der Aa, PLoS ONE	2010	305
Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and Progressive Tumours and Implications for Therapy Barthold Ph. Schrier, Maarten P. Hollander, Bas W.G. van Rhijn, European Urology Urological ResearchUrologyGenitourinary CancerMedicineCancer Prognosis	2003	267
<b> <i>FGFR3</i> </b> and <b> <i>P53</i> </b> Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma Bas W.G. van Rhijn, Theodorus van der Kwast, André N. Vis, Cancer Research Tumor BiologyP53 AlterationsUrologyUrothelial Cell CarcinomaGenitourinary Cancer	2004	219

Page 1